Robert Patrick Giugliano, M.D.
Co-Author
This page shows the publications co-authored by Robert Giugliano and Christopher Cannon.
Connection Strength
3.918
-
Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo: Analysis From IMPROVE-IT. JACC CardioOncol. 2020 Sep; 2(3):385-396.
Score: 0.224
-
Modes and timing of death in 66?252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials. Eur Heart J. 2018 11 07; 39(42):3810-3820.
Score: 0.197
-
The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol. 2018 Nov 01; 270:245-252.
Score: 0.191
-
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018 04 10; 137(15):1571-1582.
Score: 0.185
-
Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc. 2017 Nov 18; 6(11).
Score: 0.184
-
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. JAMA Cardiol. 2017 05 01; 2(5):547-555.
Score: 0.177
-
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18; 372(25):2387-97.
Score: 0.155
-
Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial. J Cardiovasc Pharmacol Ther. 2013 Nov; 18(6):555-9.
Score: 0.138
-
Relation between time of symptom onset of ST-segment elevation myocardial infarction and patient baseline characteristics: from the National Cardiovascular Data Registry. Clin Cardiol. 2013 Apr; 36(4):222-7.
Score: 0.133
-
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008 Nov; 156(5):826-32.
Score: 0.097
-
Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005 Apr 21; 352(16):1646-54.
Score: 0.077
-
Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT. J Am Heart Assoc. 2022 02 15; 11(4):e022733.
Score: 0.062
-
Reply: Analyzing IMPROVE-IT Beyond LDL Cholesterol. J Am Coll Cardiol. 2022 02 01; 79(4):e153.
Score: 0.062
-
Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. J Am Coll Cardiol. 2021 10 12; 78(15):1499-1507.
Score: 0.060
-
Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Am Heart J. 2001 May; 141(5):742-50.
Score: 0.058
-
Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 02 16; 143(7):685-695.
Score: 0.058
-
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021 02 02; 143(5):470-478.
Score: 0.057
-
Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction With Statins, Ezetimibe, and PCSK9 Inhibition. JAMA Cardiol. 2020 Nov 13.
Score: 0.057
-
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020 11 21; 396(10263):1637-1643.
Score: 0.057
-
Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. J Am Coll Cardiol. 2020 02 25; 75(7):835-837.
Score: 0.054
-
Outcomes of Women Compared With Men After Non-ST-Segment Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2019 12 17; 74(24):3013-3022.
Score: 0.053
-
Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2019 09 01; 4(9):846-854.
Score: 0.052
-
Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. J Am Coll Cardiol. 2019 08 27; 74(8):1057-1068.
Score: 0.052
-
Medication Discontinuation in the IMPROVE-IT Trial. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e005041.
Score: 0.050
-
TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation. 1998 Dec 22-29; 98(25):2805-14.
Score: 0.049
-
Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol. 2018 12; 6(12):934-943.
Score: 0.049
-
Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)". Circulation. 2018 06 12; 137(24):2662-2663.
Score: 0.048
-
Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2017 Dec 19; 136(25):2440-2450.
Score: 0.046
-
Reply: Ezetimibe, Risk Stratification, and Secondary Prevention. J Am Coll Cardiol. 2017 08 29; 70(9):1200.
Score: 0.045
-
Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circ Cardiovasc Qual Outcomes. 2017 05; 10(5).
Score: 0.044
-
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. J Am Coll Cardiol. 2017 Feb 28; 69(8):911-921.
Score: 0.044
-
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J. 2016 Dec; 182:89-96.
Score: 0.042
-
The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur Heart J. 2016 Dec 21; 37(48):3576-3584.
Score: 0.042
-
Reply: Personalize and Optimize Lipid-Lowering Therapies. J Am Coll Cardiol. 2016 07 19; 68(3):326.
Score: 0.042
-
Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful? J Am Coll Cardiol. 2016 06 28; 67(25):3025-6.
Score: 0.042
-
Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". Circulation. 2016 Mar 29; 133(13):e463.
Score: 0.041
-
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. J Am Coll Cardiol. 2016 Feb 02; 67(4):353-361.
Score: 0.041
-
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. Am Heart J. 2016 Jan; 171(1):25-32.
Score: 0.040
-
Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015 Sep 29; 132(13):1224-33.
Score: 0.039
-
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014 Aug; 168(2):205-12.e1.
Score: 0.036
-
Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. Clin Cardiol. 2014 Mar; 37(3):160-6.
Score: 0.035
-
Circadian variation in patient characteristics and outcomes in ST-segment elevation myocardial infarction. Chronobiol Int. 2012 Dec; 29(10):1390-6.
Score: 0.032
-
Prior aspirin use and outcomes in acute coronary syndromes. J Am Coll Cardiol. 2010 Oct 19; 56(17):1376-85.
Score: 0.028
-
An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010 May; 159(5):705-9.
Score: 0.027
-
Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan; 159(1):55-62.
Score: 0.027
-
Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. Am Heart J. 2009 Apr; 157(4):673-9.e1.
Score: 0.025
-
Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. J Am Coll Cardiol. 2008 Sep 09; 52(11):914-20.
Score: 0.024
-
The independent and combined risk of diabetes and non-endstage renal impairment in non-ST-segment elevation acute coronary syndromes. Int J Cardiol. 2008 Dec 17; 131(1):105-12.
Score: 0.023
-
The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol. 2006 Jul 04; 48(1):37-42.
Score: 0.021
-
Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome. J Clin Hypertens (Greenwich). 2006 May; 8(5):315-22.
Score: 0.021
-
Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials). J Thromb Thrombolysis. 2006 Apr; 21(2):119-29.
Score: 0.021
-
U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jul 05; 46(1):178-80.
Score: 0.019
-
Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy. Am J Cardiol. 2005 Feb 01; 95(3):337-42.
Score: 0.019
-
Association of a negative residual stenosis following rescue/adjunctive percutaneous coronary intervention with impaired myocardial perfusion and adverse outcomes among ST-segment elevation myocardial infarction patients. J Am Coll Cardiol. 2005 Feb 01; 45(3):357-62.
Score: 0.019
-
Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jan 18; 45(2):321-3.
Score: 0.019
-
Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. Am J Cardiol. 2005 Jan 15; 95(2):224-7.
Score: 0.019
-
Association of platelet count with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Dec 01; 94(11):1406-10.
Score: 0.019
-
Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol. 2004 Nov 01; 94(9):1113-7.
Score: 0.019
-
Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004 Nov; 25(22):1998-2005.
Score: 0.019
-
Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Sep 01; 44(5):980-7.
Score: 0.018
-
Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Aug 18; 44(4):783-9.
Score: 0.018
-
Association of lesion complexity following fibrinolytic administration with mortality in ST-elevation myocardial infarction. Am J Cardiol. 2004 Jul 01; 94(1):108-11.
Score: 0.018
-
The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies. Eur Heart J. 2004 Jul; 25(13):1139-45.
Score: 0.018
-
Association of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction. J Thromb Thrombolysis. 2004 Jun; 17(3):177-84.
Score: 0.018
-
Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. J Am Coll Cardiol. 2004 Apr 07; 43(7):1170-6.
Score: 0.018
-
Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation. 2004 Feb 10; 109(5):580-6.
Score: 0.018
-
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation. 2004 Feb 24; 109(7):874-80.
Score: 0.018
-
Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003 Nov 05; 42(9):1535-43.
Score: 0.017
-
Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003 Jul 02; 42(1):7-16.
Score: 0.017
-
Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. J Thromb Thrombolysis. 2003 Jun; 15(3):189-96.
Score: 0.017
-
Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol. 2001 Oct 15; 88(8):831-6.
Score: 0.015
-
Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA. 2001 Sep 19; 286(11):1356-9.
Score: 0.015
-
Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. Am J Cardiol. 2001 Aug 15; 88(4):353-8.
Score: 0.015
-
Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials). Am J Cardiol. 2000 Jun 15; 85(12):1409-13.
Score: 0.014
-
High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation. 2000 Jun 13; 101(23):2690-5.
Score: 0.014
-
Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999 Nov 01; 34(5):1403-12.
Score: 0.013
-
Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction. The TIMI Study Group. Thrombolysis in myocardial infarction. J Am Coll Cardiol. 1999 Oct; 34(4):974-82.
Score: 0.013
-
Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. The TIMI Study Group. Am Heart J. 1999 Jun; 137(6):1179-84.
Score: 0.013
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.